Expression Analysis of SPARC/Osteonectin in Oral Squamous Cell Carcinoma Patients: From Saliva to Surgical Specimen

Figure 1

Representative hematoxylin/eosine and SPARC immunostaining on a prognostic oral squamous cell carcinoma (OSCC) TMA. (a, b) E/E (20x–40x); (c, d) high SPARC cytoplasmatic expression (20x–40x); (e, f) low SPARC cytoplasmatic expression (20x–40x); (g, h) negative SPARC tumoral expression in OSCC and strong SPARC immunostaining in stromal tissue (20x–40x).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)